Rare Bone Tumors Drive Phosphate Wasting Through FGF23 and FGFR1 Pathways

Phosphaturic mesenchymal tumors (PMTs) are uncommon neoplasms arising in bone or soft tissue that carry outsized clinical consequences relative to their rarity. By secreting the phosphate-regulating hormone FGF23, these tumors drive tumor-induced osteomalacia — a paraneoplastic syndrome characterized by renal phosphate wasting, hypophosphatemia, and progressive bone pain and fractures. Diagnosis is frequently delayed because the tumors are small and histologically variable, and the syndrome mimics other metabolic bone disorders.

This 2025 review by Su and Lee synthesizes current clinical, pathologic, and molecular knowledge of PMTs. Histologically, PMTs display bland spindled cells embedded in a highly vascularized stroma with characteristic 'smudgy or grungy' calcified matrix and osteoclast-like giant cells — features that must be distinguished from a range of histologic mimics including hemangiopericytoma, solitary fibrous tumor, and giant cell tumors.

A key molecular update is the elucidation of tumorigenesis mechanisms. Most PMTs harbor FN1::FGFR1 or FN1::FGF1 gene fusions that constitutively activate the FGFR1 signaling axis, driving FGF23 overproduction. In fusion-negative PMTs, α-Klotho overexpression appears to serve as an alternative mechanism activating the same pathway, broadening the molecular landscape.

These findings carry therapeutic implications. FGFR1 pathway inhibitors — already in oncologic use for other malignancies — represent a rational targeted approach for unresectable or recurrent PMTs, which historically have had limited treatment options beyond surgical excision.

As a review article based solely on the abstract, detailed outcome data and patient cohort specifics are not available for critical appraisal. Nonetheless, this synthesis provides clinicians and pathologists with an actionable framework for diagnosis, molecular workup, and emerging treatment strategies for this rare but morbid tumor.